Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters

The early diagnosis of Alzheimer's disease is essential to enable patients to have access to the available treatments. However, there is a delay between the diagnosis and the onset of symptoms, which can range from 1 year to more than 5 years. In clinical practice, the hippocampal volume, measured by the Scheltens index, is currently used as a marker of the progression of the disease.

The purpose of this study is to determine whether the patient's sex, age and ethnicity can influence the delay in the expression of cognitive troubles reported by the family at the first medical consultation, as well as to determine if there is a correlation between the delay reported by the family and the Scheltens index.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Brugmann

Brussels, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria

Exclusion criteria

None

Treatment and study plan

Medical file data extraction

Other

Medical file data extraction

Primary outcomes

Age

Time frame: Between 01-01-2010 and 31-01-2013

Age
Sex

Time frame: Between 01-01-2010 and 31-01-2013

Sex
Ethnic origin

Time frame: Between 01-01-2010 and 31-01-2013

Ethnic origin
Symptoms-diagnose time interval

Time frame: Between 01-01-2010 and 31-01-2013

Interval of time between the apparition of the first symptoms, as reported by the family, and the diagnose.
Scheltens scale

Time frame: Between 01-01-2010 and 31-01-2013

Evaluation of the hippocampal atrophy by means of magnetic resonance imaging. Scale from 0 (normal) to 4.

Sponsors and collaborators

Lead sponsor

Murielle Surquin

Other

Registry information

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2017
First posted: Jan 23, 2018
Registry last updated: Jan 23, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed